"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."
CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."
AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA
"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."
"The Bay Area offers a confluence of universities, investors and companies, and we are interested in strengthening bridges between these institutions to streamline the process of technology translation."
"Given that a significant amount of intellectual property and cutting-edge science resides within smaller companies, we created a purpose-built firm to help smaller players develop their products and bring them to market."
Investors once came to Mongolia for its geology yet stumbled upon its legislative framework. How competitive Mongolia has become today, we will leave our readers to judge, hoping that this report provides them with the resources to make an informed assessment.